<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://latebreakingscience.com/wp-content/plugins/seriously-simple-podcasting/templates/feed-stylesheet.xsl?v=2"?><rss version="2.0"
	 xmlns:content="http://purl.org/rss/1.0/modules/content/"
	 xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	 xmlns:dc="http://purl.org/dc/elements/1.1/"
	 xmlns:atom="http://www.w3.org/2005/Atom"
	 xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	 xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	 xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
	 xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"
	 xmlns:podcast="https://podcastindex.org/namespace/1.0"
	 xmlns:ssp="https://castos.com/seriously-simple-podcasting/namespace/1.0"
	>
		<channel>
		<title>ESMO 2021</title>
		<atom:link href="https://latebreakingscience.com/feed/podcast/esmo-2021/" rel="self" type="application/rss+xml"/>
		<link>https://latebreakingscience.com/series/esmo-2021/</link>
		<description>European Society of Medical Oncology. Prostate Cancer Conference Highlights </description>
		<lastBuildDate>Thu, 20 Nov 2025 14:00:44 +0000</lastBuildDate>
		<language>en-US</language>
		<copyright>&#xA9; 2026 Late Breaking Science</copyright>
		<itunes:subtitle>European Society of Medical Oncology. Prostate Cancer Conference Highlights </itunes:subtitle>
		<itunes:author>Late Breaking Science</itunes:author>
		<itunes:summary>European Society of Medical Oncology. Prostate Cancer Conference Highlights </itunes:summary>
		<itunes:owner>
			<itunes:name>Late Breaking Science</itunes:name>
		</itunes:owner>
		<itunes:explicit>false</itunes:explicit>
		<itunes:image href="https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg"></itunes:image>
			<image>
				<url>https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg</url>
				<title>ESMO 2021</title>
				<link>https://latebreakingscience.com/series/esmo-2021/</link>
			</image>
		<googleplay:author><![CDATA[Late Breaking Science]]></googleplay:author>
						<googleplay:description>European Society of Medical Oncology. Prostate Cancer Conference Highlights </googleplay:description>
			<googleplay:explicit>No</googleplay:explicit>
			<googleplay:image href="https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg"></googleplay:image>
			<podcast:locked>yes</podcast:locked>
		<podcast:guid>ec254604-a78b-5443-b54e-de8373b54a2b</podcast:guid>
		
		<!-- podcast_generator="SSP by Castos/3.16.0" Seriously Simple Podcasting plugin for WordPress (https://wordpress.org/plugins/seriously-simple-podcasting/) -->
		<generator>https://wordpress.org/?v=7.0</generator>

<item>
	<title>Dr. Andre-Guy Martin</title>
	<link>https://latebreakingscience.com/podcast/dr-andre-guy-martin/</link>
	<pubDate>Thu, 07 Oct 2021 18:57:29 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=710</guid>
	<description><![CDATA[Abstract 576MO &#8211; Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer]]></description>
	<itunes:subtitle><![CDATA[Abstract 576MO &#8211; Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 576MO &#8211; Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/710/dr-andre-guy-martin.mp3" length="14529580" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 576MO &#8211; Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>7:29</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 576MO &#8211; Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Jenny Ko</title>
	<link>https://latebreakingscience.com/podcast/dr-jenny-ko/</link>
	<pubDate>Thu, 07 Oct 2021 18:56:27 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=709</guid>
	<description><![CDATA[Abstract LBA26 – Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial (SAKK 08/16)]]></description>
	<itunes:subtitle><![CDATA[Abstract LBA26 – Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: A multicenter r]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract LBA26 – Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial (SAKK 08/16)]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/709/dr-jenny-ko.mp3" length="15413010" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract LBA26 – Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial (SAKK 08/16)]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>7:57</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract LBA26 – Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial (SAKK 08/16)]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Maria Jiang</title>
	<link>https://latebreakingscience.com/podcast/dr-maria-jiang/</link>
	<pubDate>Thu, 07 Oct 2021 18:55:55 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=708</guid>
	<description><![CDATA[Abstract LBA25 – Final overall survival (OS) analysis from ARCHES: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)]]></description>
	<itunes:subtitle><![CDATA[Abstract LBA25 – Final overall survival (OS) analysis from ARCHES: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (m]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract LBA25 – Final overall survival (OS) analysis from ARCHES: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/708/dr-maria-jiang.mp3" length="25069534" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract LBA25 – Final overall survival (OS) analysis from ARCHES: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>12:55</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract LBA25 – Final overall survival (OS) analysis from ARCHES: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Geoffrey Gotto</title>
	<link>https://latebreakingscience.com/podcast/dr-geoffrey-gotto/</link>
	<pubDate>Thu, 07 Oct 2021 18:55:05 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=707</guid>
	<description><![CDATA[Abstract LBA4 – Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol]]></description>
	<itunes:subtitle><![CDATA[Abstract LBA4 – Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two ]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract LBA4 – Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/707/dr-geoffrey-gotto.mp3" length="17765880" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract LBA4 – Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>9:09</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract LBA4 – Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr Aly-Khan Lalani</title>
	<link>https://latebreakingscience.com/podcast/dr-aly-khan-lalani/</link>
	<pubDate>Mon, 27 Sep 2021 15:44:36 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=682</guid>
	<description><![CDATA[Abstract LBA5 – A phase 3 trial with a 2&#215;2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1]]></description>
	<itunes:subtitle><![CDATA[Abstract LBA5 – A phase 3 trial with a 2&#215;2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract LBA5 – A phase 3 trial with a 2&#215;2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/682/dr-aly-khan-lalani.mp3" length="29236000" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract LBA5 – A phase 3 trial with a 2&#215;2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>15:10</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract LBA5 – A phase 3 trial with a 2&#215;2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>
	</channel>
</rss>
